

		<b>EMLc</b>	ATC codes: <b>L01BB02</b>
<b>Indication</b>	Acute myeloid leukaemia with recurrent genetic abnormalities	ICD11 code: <b>2B30.0</b>	
<b>INN</b>	Mercaptopurine		
<b>Medicine type</b>	Chemical agent		
<b>List type</b>	Complementary (EML) (EMLc)		
<b>Formulations</b>	Oral > Liquid: 20 mg per mL (EMLc) Oral > Solid: 50 mg tablet		
<b>EML status history</b>	First added in 2015 ( <a href="#">TRS 994</a> ) Changed in 2019 ( <a href="#">TRS 1021</a> ) Changed in 2023 ( <a href="#">TRS 1049</a> )		
<b>Sex</b>	All		
<b>Age</b>	Also recommended for children		
<b>Therapeutic alternatives</b>	The recommendation is for this specific medicine		
<b>Patent information</b>	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 		
<b>Tags</b>	<span>Cancer</span>		
<b>Wikipedia</b>	<a href="#">Mercaptopurine</a> 		
<b>DrugBank</b>	<a href="#">Mercaptopurine</a> 		

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of an additional dose form of mercaptopurine (oral liquid 20 mg/mL) to the EMLc.

